Cambridge, UK, 7 July 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Dr Stuart Wood as Vice President of Discovery Technology.
Stuart has held a series of leadership roles in Biotech for over ten years, most recently as Chief Technology Officer at Nanna Therapeutics. Across his roles, Stuart has worked to develop novel solid state nanopore sequencing systems, and applied microfluidic solutions to increase throughput of a range of biochemical and cellular assay systems. More recently at Nanna, Stuart developed a microdroplet screening platform for natural products and medicinal chemistry approaches which underpinned the building of the technology platforms and therapeutic areas at Nanna.
As Nanna grew from two to over twenty staff, Stuart was central to the build of the company and development of early therapeutic programs to tackle mitochondrial dysfunction with application in rare diseases and neurodegeneration in partnership with clinical and academic groups through to the company’s acquisition in 2020 by Astellas.
Stuart began his scientific career working on bacterial genetics & biochemistry studying DNA repair and homologous recombination. He moved to Cambridge to undertake a career development fellowship at the MRC Mitochondrial Biology Unit. Here he studied how errors in mitochondrial DNA replication and transcription led to human disease, developing novel techniques to study mitochondrial nucleic acids.
Amphista’s CSO Dr Ian Churcher said, “On behalf of everyone at Amphista, I am delighted to welcome Stuart to the R&D leadership team. Stuart’s outstanding track record of constant innovation and successful development & application of novel technology strategies to drug discovery projects will enable us to further accelerate the development of Amphista’s next generation Targeted Protein Degradation platform and therapeutic portfolio.”
Amphista’s new VP of Discovery Technology, Dr Stuart Wood, commented on his appointment, “I’m excited to be joining the Amphista team and working alongside many of their pioneers and leaders in the TPD field, an area where there are so many opportunities to apply new technology solutions to the identification and optimisation of new protein degrading drugs. TPD has the potential to deliver transformational medicines and Amphista’s approach promises to overcome many of the limitations now emerging with first generation TPD approaches.”
– Ends –
+44 7464 974714
Berry & Company Public Relations
+1 212 253 8881
About Amphista Therapeutics
Amphista Therapeutics is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD), which address the challenges faced by the field and to realise the full therapeutic potential of this transformational approach. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s labs at the University of Dundee. The company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly & Company.
For more information, please visit: https://amphista.com/